HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with two major industry players already taking part in a pilot program.

By FierceBiotech · Apr 29, 2026 · via FierceBiotech
FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech

Tags
policyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts
PolicyFiercePharma ↗
Eleventh-hour settlements with two of the three generic drugmakers involved could bode well for both Pfizer an…
Apr 29, 2026
PolicyAJMC ↗
Apr 28, 2026
PolicySTAT News ↗
The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny label…
Apr 28, 2026